Mikhail Eydelman serves as the Senior Vice President, General Counsel, and Corporate Secretary at VAXCYTE INC, a leading biotechnology company focused on developing novel vaccines. In his role, Eydelman is responsible for overseeing the company's legal affairs, ensuring compliance with regulatory requirements, and providing strategic guidance to the executive team. His expertise in corporate governance and intellectual property law has been instrumental in navigating the complex landscape of the biotechnology industry. Prior to joining VAXCYTE INC, Eydelman held several high-profile positions in the legal field. He spent over a decade at a prestigious international law firm, where he specialized in mergers and acquisitions, securities law, and corporate finance. During his tenure, he advised numerous biotechnology and pharmaceutical companies on a wide range of legal matters, including IPOs, strategic partnerships, and licensing agreements. Eydelman's deep understanding of the industry and his ability to provide practical solutions to complex legal challenges have earned him a reputation as a trusted advisor. Eydelman's contributions to VAXCYTE INC have been significant. Under his leadership, the company has successfully navigated several key milestones, including the advancement of its lead vaccine candidate through clinical trials and the establishment of strategic collaborations with industry partners. His strategic vision and commitment to excellence have played a crucial role in positioning VAXCYTE INC as a leader in the development of innovative vaccines. Eydelman's dedication to the company's mission and his ability to foster a culture of integrity and transparency have made him an invaluable member of the executive team.